Kalvista Pharmaceuticals Inc (KALV) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Jan 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kalvista Pharmaceuticals Inc   (NASDAQ: KALV)

Kalvista Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Kalvista Pharmaceuticals Inc in the first quarter 2026?
Kalvista Pharmaceuticals Inc recorded a cumulative net loss of $-185 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -555.06%.

Within the Major Pharmaceutical Preparations industry 328 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 3177 to 3237.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Sep 30 2025)
III. Quarter		 (Jul 31 2025)
I. Quarter		 (Apr 30 2025)
IV. Quarter		 (Jan 31 2025)
III. Quarter
Y / Y Equity Change - -53.82 % -87.31 % -76.39 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -185 -210 -203 -183 -176
Return On Equity (TTM) -555.06 % -338.43 % -225.81 % -153.91 % -115.56 %
KALV's Total Ranking # 3237 # 3177 # 3290 # 3343 #
Equity (TTM) in Millions -20 95 17 41 95
Seq. Equity Change - 461.16 % -58.33 % -57.24 % -53.82 %
Seq. Net Income Change - - - - -

Back to KALV Management Effectiveness >> KALV's 5 Years Annual ROE >> Compare KALV ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 329
Sector # 670
Overall # 3237

Return On Equity Statistics
High Average Low
-19.58 %
-79.56 %
-555.06 %
(Jan 31 2019)   (Mar 31 2026)





KALV Annual Return On Equity (Apr 30 2025)
2025		 (Apr 30 2024)
2024		 (Apr 30 2023)
2023		 (Apr 30 2022)
2022		 (Apr 30 2021)
2021
Total Equity in Millions 95 207 161 185 257
Y / Y Equity Change -53.82 % 28.29 % -13 % -28.03 % 207.09 %
Net Income in Millions -183 -127 -93 -82 -46
Y / Y Net Income Change - - - - -
Return On Equity -192.31 % -61.3 % -57.7 % -44.49 % -17.98 %

Back to KALV Management Effectiveness >> KALV's 5 Years Annual ROE >> Compare KALV ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
KALV's' Return on Equity at Yahoo Finance
KALV's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for KALV's Competitors
Subscribers only: Roe for Kalvista Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for KALV's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE

Date modified: 2026-09-26T07:07:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.